Why You Should Be Excited About GW Pharma
GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) could become a one-of-its-kind company if the FDA approves the company's cannabis-based drug for child epilepsy as a late-stage study showed positive results.
The company also commenced a Phase 3 clinical trial of Epidiolex as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder.
However, the stock has been volatile. It fell to $36 in early March only to bounce to $84 a few weeks later.
Alan Brochstein spoke about GW Pharma on Wednesday's PreMarket Prep.
"They are making tremendous efforts. I am surprised at what happened at the beginning of the year. Biotech market was melting down, so that was a part of it. Luckily I held positions in the stock," Brochstein said.
GW Pharma is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), which is in Phase study for the treatment of Dravet syndrome, Lennox-Gastaut syndrome and Tuberous Sclerosis Complex. The company also has a pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, schizophrenia and epilepsy.
"I like this story. Since, it is biotech, it is risky," he added.
PreMarket Prep is a daily interactive trading show that features interviews with fund managers, financial advisors and executives. Listen to the show live from 8-9:30 a.m. EST here, or listen to the podcast here.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: #PreMarket Prep Alan BrochsteinHealth Care Trading Ideas Interview General
